# Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

> **NCT04689100** · PHASE1 · UNKNOWN · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 259 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** JMT101
- **DRUG:** JMT101

## Key facts

- **NCT ID:** NCT04689100
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-11
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 259 (ESTIMATED)
- **Last updated:** 2020-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04689100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04689100, "Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04689100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*